Verrica Pharmaceuticals Inc. Total Liabilities and Equity
Verrica Pharmaceuticals Inc. (VRCA) had Total Liabilities and Equity of $36.02 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-06
- 2026-06-30: Liabilities and Equity $36.02M.
- 2026-03-31: Liabilities and Equity $38.79M.
- 2025-12-31: Liabilities and Equity $47.13M.
- 2025-09-30: Liabilities and Equity $40.90M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $36.02M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $38.79M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $47.13M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $40.90M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $39.11M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $42.18M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $54.13M 10-K · filed 2026-03-11 |
| 2024-09-30 | $32.93M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $52.01M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $66.31M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $81.60M 10-K · filed 2025-03-11 |
| 2023-09-30 | $97.15M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $62.20M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $68.64M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $44.72M 10-K · filed 2024-02-29 |
| 2022-09-30 | $49.15M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $63.44M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $71.62M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $80.13M 10-K · filed 2023-03-06 |
| 2021-09-30 | $88.76M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $99.03M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $108.10M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $74.15M 10-K · filed 2022-03-02 |
| 2020-09-30 | $79.94M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $87.24M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $94.44M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $68.42M 10-K · filed 2021-03-17 |
| 2019-09-30 | $76.07M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $81.25M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $85.98M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $91.91M 10-K · filed 2020-03-13 |
| 2018-09-30 | $98.81M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $104.72M 10-Q · filed 2018-08-07 |
| 2017-12-31 | $9.08M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |